Market revenue in 2023 | USD 315.2 million |
Market revenue in 2030 | USD 466.4 million |
Growth rate | 5.8% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Novartis AG ADR, Labcorp Holdings Inc, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, GlaxoSmithKline Consumer Healthcare (GSK CH India), Aurora Innovation Inc Class A, Biogen Inc, IQVIA Holdings Inc, inVentiv Health |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to neurology clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 46.76% in 2023. Horizon Databook has segmented the Germany neurology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Germany is another key location for clinical trials in Europe. Advancements in technology and highquality clinical resources are some of the primary factors expected to propel the market growth over the forecast period. The presence of a significant number of CROs and pharmaceutical companies in the country conducting neurology clinical trials is likely to contribute to market growth.
However, high overhead cost is a major challenge in this region, due to which companies are shifting the location of their clinical trials to developing economies. The global share of Germany in clinical trial activity is declining consistently compared to other European countries.
According to Global Data, Germany’s clinical trials accounted for 4.9% of the global clinical trial activity in 2018, whereas in 2021, they accounted for 3.9%. The consistent decline in clinical trial activity in Germany is likely to impact the neurology clinical trials market in Germany.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany neurology clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Germany neurology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account